Resources for journalists covering peptide therapy safety, provider verification, and the compounding pharmacy landscape.
The peptide therapy market exceeds $2B annually, yet patients have no standardized way to verify provider legitimacy. PepKey's data shows that zero (0) providers currently score at the GREEN tier (8.0+) — because GREEN requires claiming a listing. 152 providers score at the TEAL tier (5.75+). The average unclaimed provider score is 3.5/10.
With the FDA's evolving stance on compounded peptides (including semaglutide and tirzepatide), patients face growing confusion about what they're actually receiving. PepKey tracks provider transparency on compounding disclosures.
PepKey maintains the largest independent database of peptide therapy providers in the United States. Our scoring methodology evaluates medical oversight, prescribing transparency, pharmacy sourcing, and NPI cross-reference across 7,362 providers in all 50 states.
Download PepKey logos, wordmarks, and brand guidelines for media use.
Mike Paepke is a physician assistant with training from Yale's PA program and a fellowship in orthopedics. His graduate research focused on peptide therapeutics and long-term medical costs. He founded PepKey to address the trust gap he observed firsthand in the peptide therapy market.
Available for interviews on: peptide therapy safety, provider verification, compounding pharmacy regulation, patient advocacy in cash-pay medicine.
